FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, announced the results from its first human kidney cancer treatments using the Sonatherm 600 (“Sonatherm”), a medical device using high intensity focused ultrasound (“HIFU”). According to Dr. Michael A. Marberger, Chairman and Professor of the Department of Urology, University of Vienna Medical School, Vienna, Austria, where the treatments were performed, procedures were successfully completed with positive ablation effect noted on cancer cells in tumors within human kidneys.
